FTSE 100 news / Companies and sectors / AstraZeneca / 15 October 2026
AstraZeneca (AZN): news on Thursday 15 October 2026
+7.5 strongly positive
Coverage centred on a sharp share price rise, with upgrades, higher price targets and oncology deals cited. A clinical trial partnership with NIPER Raebareli in India and Phase III results added to the positive tone, though one technical note was bearish.
What drove it
- share price rally
- analyst upgrades
- India trial partnership
The 30 stories
- +10.0 AstraZeneca Stock Price Forecast — AZN ($161.59) Rallies 3.7% Off 52-Week Low on Defensive Bid and Double Upgrade — $169 Target
Rally off low with double upgrade and higher target - +9.3 AstraZeneca PLC Stock Draws Upgrades As Oncology Deals Accelerate
Upgrades as oncology deals accelerate - +9.2 FTSE 100 Climbs to 10,724.86, a Three-Week High, as AstraZeneca, GSK and Defence Stocks Lead
Shares led FTSE 100 to three-week high - +9.2 AstraZeneca PLC (AZN) Shares Surge 4.0% -- What GF Score of 76 T
Shares surged 4.0% - +9.2 AstraZeneca PLC Draws Bullish Targets As Oncology Deals Mount
Bullish targets as oncology deals mount - +8.8 AstraZeneca Stock Draws Bullish Targets As Oncology Deals Pile Up
Bullish targets on oncology deals - +8.7 AstraZeneca PLC Stock Gains Favor As Oncology Deals Mount
Stock gains favour on oncology deals - +8.3 AstraZeneca PLC Stock (AZN) Moved Up by 3.81% on Oct 14: A Full Analysis
Shares moved up 3.81% - +8.3 Why AstraZeneca (AZN) Stock Is Up Today
Stock up on the day - +8.3 Citi raises target for AstraZeneca stock to GBp 18,600 - ad-hoc-news.de
Citi raised price target - +7.5 AstraZeneca reports HICKORY Phase III results for AstraZeneca stock - ad-hoc-news.de
Phase III HICKORY results reported - +6.7 Is New Cambridge R And D Hub Altering The Investment Case For AstraZeneca (LSE:AZN)?
New Cambridge R&D hub considered for investment case - +6.3 AstraZeneca’s LAZURE Trial Signals Next Step in Cholesterol Treatment
Cholesterol trial progress - +6.0 NIPER Raebareli and AstraZeneca India partner to build clinical trial sites in 25 non-metro hubs
Clinical trial sites partnership in 25 non-metro hubs - +5.8 NIPER Raebareli, AstraZeneca partner to boost clinical trials | Tap to know more | Inshorts
Partnership to expand clinical trial capacity in India - +5.8 NIPER Raebareli and AstraZeneca India Partner to Strengthen Clinical Research Capabilities Across 25 Emerging Geographies
Official release on clinical research partnership - +5.8 NIPER Raebareli and AstraZeneca India partner to strengthen clinical research capabilities
Clinical research capability partnership - +5.8 NIPER Raebareli, AstraZeneca India Partner to Strengthen Clinical Trial Ecosystem
India clinical trial partnership - +5.8 NIPER Raebareli, AstraZeneca India partner to expand clinical trial sites across India
Expanding trial sites across India - +5.8 NIPER Raebareli & AstraZeneca Team Up to Transform India’s Clinical Trials
Partnership to transform India's clinical trials - +5.8 NIPER Raebareli and AstraZeneca to Expand Clinical Trials to 25 Emerging Hubs
Clinical trials expansion to 25 hubs - +5.7 AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites
Upgrading clinical trial sites in India - +5.7 NIPER Raebareli and AstraZeneca India partner to boost clinical trial sites in 25 regions
Clinical trial sites partnership - +5.7 NIPER Raebareli, AstraZeneca partner to strengthen 25 clinical trial sites beyond metros
Strengthening trial sites beyond metros - +5.5 NIPER Raebareli, AstraZeneca Partner on Clinical Research
Clinical research partnership - +5.0 AstraZeneca Summit Deal: What Does Completion Unlock?
Deal completion discussed as potentially positive - −5.0 AstraZeneca shares technical analysis: Downward move persists as seller pressure dominates
Technical analysis notes persistent downward pressure - +2.0 Leora Horn: Calling Early-Career Physicians to AstraZeneca’s 2027 Scholars Program
Scholars programme call for physicians - +1.7 Filippo Fontana: Honored to Begin a New Chapter as Country President of AstraZeneca Brazil
Routine Brazil leadership appointment - +0.3 AstraZeneca PLC : Deutsche Bank reiterates its Neutral rating
Neutral rating reiterated
AstraZeneca: every day · Pharma and healthcare on 15 October 2026 · FTSE 100 overview for the day